Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Increase in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 154,542 shares, a growth of 116.7% from the December 15th total of 71,326 shares. Based on an average daily volume of 86,690 shares, the short-interest ratio is presently 1.8 days. Currently, 2.3% of the company’s stock are sold short. Currently, 2.3% of the company’s stock are sold short. Based on an average daily volume of 86,690 shares, the short-interest ratio is presently 1.8 days.

Institutional Trading of Calidi Biotherapeutics

An institutional investor recently bought a new position in Calidi Biotherapeutics stock. Warberg Asset Management LLC acquired a new stake in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned approximately 0.55% of Calidi Biotherapeutics as of its most recent SEC filing. 12.53% of the stock is currently owned by institutional investors.

Calidi Biotherapeutics Stock Performance

Shares of CLDI traded down $0.01 during trading hours on Friday, reaching $1.04. 90,560 shares of the company traded hands, compared to its average volume of 76,518. The business has a fifty day moving average price of $1.34 and a 200-day moving average price of $2.70. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12. Calidi Biotherapeutics has a 12-month low of $1.01 and a 12-month high of $19.20.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) earnings per share for the quarter. On average, sell-side analysts predict that Calidi Biotherapeutics will post -4.48 earnings per share for the current fiscal year.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.